Economic Impact of Alvimopan Considering Varying Definitions of Postoperative Ileus

Stephanie R. Earnshaw, Teresa L. Kauf, Cheryl McDade, Michele H. Potashman, Cassandra Pauyo, Emily S. Reese, Anthony Senagore

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background Prolonged postoperative ileus (POI) is the predominant cause of extended hospitalization after bowel resection surgery. Alvimopan accelerates gastrointestinal recovery, potentially reducing health care costs. We examined the value of alvimopan in reducing prolonged POI and length of stay for patients undergoing abdominal surgery using different definitions of POI. Study Design We developed a decision analytic model to examine costs and outcomes associated with postoperative treatment with either an accelerated care pathway (ACP) only or alvimopan+ACP. To represent an overall perspective for alvimopan, data from four phase 3 bowel resection trials and one phase 4 radical cystectomy trial were used to populate the model with 3 different definitions of POI. The period analyzed included start of surgery to 7 days post discharge. Costs were obtained from standard US costing sources and are reported in 2015 US dollars. Due to variations in published definitions of POI, alternative definitions based on adverse event reports, NG tube insertion, and time to food toleration were examined. Results The combined clinical trial data included 1,003 ACP and 1,013 alvimopan+ACP patients. When POI was reported as an adverse event, the incidence of POI was significantly lower with alvimopan+ACP (n = 70 [7%]) vs ACP alone (n = 148 [15%]; p <0.0001). Time to discharge order written was shorter for patients with POI who were treated with alvimopan+ACP than with ACP (202 ± 115 hours vs 266 ± 138 hours; p <0.0001). As a result, costs were $731 lower with alvimopan+ACP ($17,835) vs ACP ($18,566). Alternative definitions of POI produced similar results. Conclusions The addition of alvimopan to existing treatment pathways for patients undergoing abdominal surgery can reduce overall hospital costs.

Original languageEnglish (US)
Pages (from-to)941-950
Number of pages10
JournalJournal of the American College of Surgeons
Volume221
Issue number5
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Fingerprint

alvimopan
Ileus
Economics
Costs and Cost Analysis
Hospital Costs
Cystectomy

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Cite this

Earnshaw, S. R., Kauf, T. L., McDade, C., Potashman, M. H., Pauyo, C., Reese, E. S., & Senagore, A. (2015). Economic Impact of Alvimopan Considering Varying Definitions of Postoperative Ileus. Journal of the American College of Surgeons, 221(5), 941-950. https://doi.org/10.1016/j.jamcollsurg.2015.08.004

Economic Impact of Alvimopan Considering Varying Definitions of Postoperative Ileus. / Earnshaw, Stephanie R.; Kauf, Teresa L.; McDade, Cheryl; Potashman, Michele H.; Pauyo, Cassandra; Reese, Emily S.; Senagore, Anthony.

In: Journal of the American College of Surgeons, Vol. 221, No. 5, 01.11.2015, p. 941-950.

Research output: Contribution to journalArticle

Earnshaw, SR, Kauf, TL, McDade, C, Potashman, MH, Pauyo, C, Reese, ES & Senagore, A 2015, 'Economic Impact of Alvimopan Considering Varying Definitions of Postoperative Ileus', Journal of the American College of Surgeons, vol. 221, no. 5, pp. 941-950. https://doi.org/10.1016/j.jamcollsurg.2015.08.004
Earnshaw, Stephanie R. ; Kauf, Teresa L. ; McDade, Cheryl ; Potashman, Michele H. ; Pauyo, Cassandra ; Reese, Emily S. ; Senagore, Anthony. / Economic Impact of Alvimopan Considering Varying Definitions of Postoperative Ileus. In: Journal of the American College of Surgeons. 2015 ; Vol. 221, No. 5. pp. 941-950.
@article{16d78eff522e4e5e9351e7c9c104b00a,
title = "Economic Impact of Alvimopan Considering Varying Definitions of Postoperative Ileus",
abstract = "Background Prolonged postoperative ileus (POI) is the predominant cause of extended hospitalization after bowel resection surgery. Alvimopan accelerates gastrointestinal recovery, potentially reducing health care costs. We examined the value of alvimopan in reducing prolonged POI and length of stay for patients undergoing abdominal surgery using different definitions of POI. Study Design We developed a decision analytic model to examine costs and outcomes associated with postoperative treatment with either an accelerated care pathway (ACP) only or alvimopan+ACP. To represent an overall perspective for alvimopan, data from four phase 3 bowel resection trials and one phase 4 radical cystectomy trial were used to populate the model with 3 different definitions of POI. The period analyzed included start of surgery to 7 days post discharge. Costs were obtained from standard US costing sources and are reported in 2015 US dollars. Due to variations in published definitions of POI, alternative definitions based on adverse event reports, NG tube insertion, and time to food toleration were examined. Results The combined clinical trial data included 1,003 ACP and 1,013 alvimopan+ACP patients. When POI was reported as an adverse event, the incidence of POI was significantly lower with alvimopan+ACP (n = 70 [7{\%}]) vs ACP alone (n = 148 [15{\%}]; p <0.0001). Time to discharge order written was shorter for patients with POI who were treated with alvimopan+ACP than with ACP (202 ± 115 hours vs 266 ± 138 hours; p <0.0001). As a result, costs were $731 lower with alvimopan+ACP ($17,835) vs ACP ($18,566). Alternative definitions of POI produced similar results. Conclusions The addition of alvimopan to existing treatment pathways for patients undergoing abdominal surgery can reduce overall hospital costs.",
author = "Earnshaw, {Stephanie R.} and Kauf, {Teresa L.} and Cheryl McDade and Potashman, {Michele H.} and Cassandra Pauyo and Reese, {Emily S.} and Anthony Senagore",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.jamcollsurg.2015.08.004",
language = "English (US)",
volume = "221",
pages = "941--950",
journal = "Journal of the American College of Surgeons",
issn = "1072-7515",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Economic Impact of Alvimopan Considering Varying Definitions of Postoperative Ileus

AU - Earnshaw, Stephanie R.

AU - Kauf, Teresa L.

AU - McDade, Cheryl

AU - Potashman, Michele H.

AU - Pauyo, Cassandra

AU - Reese, Emily S.

AU - Senagore, Anthony

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background Prolonged postoperative ileus (POI) is the predominant cause of extended hospitalization after bowel resection surgery. Alvimopan accelerates gastrointestinal recovery, potentially reducing health care costs. We examined the value of alvimopan in reducing prolonged POI and length of stay for patients undergoing abdominal surgery using different definitions of POI. Study Design We developed a decision analytic model to examine costs and outcomes associated with postoperative treatment with either an accelerated care pathway (ACP) only or alvimopan+ACP. To represent an overall perspective for alvimopan, data from four phase 3 bowel resection trials and one phase 4 radical cystectomy trial were used to populate the model with 3 different definitions of POI. The period analyzed included start of surgery to 7 days post discharge. Costs were obtained from standard US costing sources and are reported in 2015 US dollars. Due to variations in published definitions of POI, alternative definitions based on adverse event reports, NG tube insertion, and time to food toleration were examined. Results The combined clinical trial data included 1,003 ACP and 1,013 alvimopan+ACP patients. When POI was reported as an adverse event, the incidence of POI was significantly lower with alvimopan+ACP (n = 70 [7%]) vs ACP alone (n = 148 [15%]; p <0.0001). Time to discharge order written was shorter for patients with POI who were treated with alvimopan+ACP than with ACP (202 ± 115 hours vs 266 ± 138 hours; p <0.0001). As a result, costs were $731 lower with alvimopan+ACP ($17,835) vs ACP ($18,566). Alternative definitions of POI produced similar results. Conclusions The addition of alvimopan to existing treatment pathways for patients undergoing abdominal surgery can reduce overall hospital costs.

AB - Background Prolonged postoperative ileus (POI) is the predominant cause of extended hospitalization after bowel resection surgery. Alvimopan accelerates gastrointestinal recovery, potentially reducing health care costs. We examined the value of alvimopan in reducing prolonged POI and length of stay for patients undergoing abdominal surgery using different definitions of POI. Study Design We developed a decision analytic model to examine costs and outcomes associated with postoperative treatment with either an accelerated care pathway (ACP) only or alvimopan+ACP. To represent an overall perspective for alvimopan, data from four phase 3 bowel resection trials and one phase 4 radical cystectomy trial were used to populate the model with 3 different definitions of POI. The period analyzed included start of surgery to 7 days post discharge. Costs were obtained from standard US costing sources and are reported in 2015 US dollars. Due to variations in published definitions of POI, alternative definitions based on adverse event reports, NG tube insertion, and time to food toleration were examined. Results The combined clinical trial data included 1,003 ACP and 1,013 alvimopan+ACP patients. When POI was reported as an adverse event, the incidence of POI was significantly lower with alvimopan+ACP (n = 70 [7%]) vs ACP alone (n = 148 [15%]; p <0.0001). Time to discharge order written was shorter for patients with POI who were treated with alvimopan+ACP than with ACP (202 ± 115 hours vs 266 ± 138 hours; p <0.0001). As a result, costs were $731 lower with alvimopan+ACP ($17,835) vs ACP ($18,566). Alternative definitions of POI produced similar results. Conclusions The addition of alvimopan to existing treatment pathways for patients undergoing abdominal surgery can reduce overall hospital costs.

UR - http://www.scopus.com/inward/record.url?scp=84945456402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945456402&partnerID=8YFLogxK

U2 - 10.1016/j.jamcollsurg.2015.08.004

DO - 10.1016/j.jamcollsurg.2015.08.004

M3 - Article

C2 - 26353904

AN - SCOPUS:84945456402

VL - 221

SP - 941

EP - 950

JO - Journal of the American College of Surgeons

JF - Journal of the American College of Surgeons

SN - 1072-7515

IS - 5

ER -